QUINAPRIL HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for quinapril hydrochloride and what is the scope of freedom to operate?

Quinapril hydrochloride is the generic ingredient in two branded drugs marketed by Pfizer Pharms, Actavis Elizabeth, Actavis Labs Fl Inc, Ani Pharms, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Rx, Invagen Pharms, Lupin, Mylan, Pharmobedient, Prinston Inc, and Sun Pharm Inds Ltd, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for quinapril hydrochloride. Nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for QUINAPRIL HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	13
NDAs:	14
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	27
Patent Applications:	5,470
What excipients (inactive ingredients) are in QUINAPRIL HYDROCHLORIDE?	QUINAPRIL HYDROCHLORIDE excipients list
DailyMed Link:	QUINAPRIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for QUINAPRIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AHEPA University Hospital	Phase 4
University of Nebraska	Phase 4
Pfizer

See all QUINAPRIL HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for QUINAPRIL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 40MG BASE	TABLET;ORAL
		EQ 20MG BASE	TABLET;ORAL
		EQ 10MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for QUINAPRIL HYDROCHLORIDE

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for QUINAPRIL HYDROCHLORIDE

C09AA	ACE inhibitors, plain
C09A	ACE INHIBITORS, PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

US Patents and Regulatory Information for QUINAPRIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	QUINAPRIL HYDROCHLORIDE	quinapril hydrochloride	TABLET;ORAL	075504-001	Aug 24, 2007		DISCN	No	No
Sun Pharm Inds Ltd	QUINAPRIL HYDROCHLORIDE	quinapril hydrochloride	TABLET;ORAL	090800-004	Jun 18, 2009		DISCN	No	No
Ani Pharms	QUINAPRIL HYDROCHLORIDE	quinapril hydrochloride	TABLET;ORAL	075504-003	Aug 24, 2007		DISCN	No	No
Aurobindo Pharma Ltd	QUINAPRIL HYDROCHLORIDE	quinapril hydrochloride	TABLET;ORAL	202725-004	Apr 29, 2013	AB	RX	No	No

Expired US Patents for QUINAPRIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer Pharms	ACCUPRIL	quinapril hydrochloride	TABLET;ORAL	019885-003	Nov 19, 1991
Pfizer Pharms	ACCUPRIL	quinapril hydrochloride	TABLET;ORAL	019885-004	Nov 19, 1991
Pfizer Pharms	ACCUPRIL	quinapril hydrochloride	TABLET;ORAL	019885-002	Nov 19, 1991
Pfizer Pharms	ACCUPRIL	quinapril hydrochloride	TABLET;ORAL	019885-003	Nov 19, 1991

Market Dynamics and Financial Trajectory for Quinapril Hydrochloride

Last updated: July 27, 2025

Introduction

Quinapril hydrochloride, an angiotensin-converting enzyme (ACE) inhibitor, is primarily prescribed for managing hypertension and congestive heart failure. Since its introduction, quinapril has contributed significantly to cardiovascular therapeutics. Understanding its market dynamics and financial trajectory requires examining factors such as patent status, competitive landscape, regulatory influences, and evolving clinical guidelines.

Market Landscape and Therapeutic Role

The global ACE inhibitors market, valued at approximately USD 6 billion in 2022, is projected to expand at a compound annual growth rate (CAGR) of 4.5% through 2030 [1]. Quinapril, while not the leading ACE inhibitor globally—competing with drugs like enalapril and ramipril—maintains a dedicated segment due to its favorable efficacy profile and tolerability.

In the cardiovascular disease (CVD) management space, quinapril is frequently prescribed alongside other antihypertensives and diuretics. Its versatility in monotherapy or combination therapy cements its role in clinical practice. Its prescribing patterns are influenced by local guidelines aligned with the American Heart Association (AHA) and European Society of Cardiology (ESC), which endorse ACE inhibitors as first-line agents for hypertension and heart failure.

Patent and Regulatory Landscape

Quinapril hydrochloride was approved by the FDA in 1989, with patent protection generally expiring around 2004-2005, depending on jurisdiction [2]. The expiration of patent rights led to the proliferation of generic quinapril formulations, significantly affecting pricing and market share dynamics. Consequently, generic quinapril accounts for up to 80% of prescriptions in some regions, creating a competitive environment that sustains affordability but constrains the financial potential for brand-name manufacturers.

Regulatory standards recognize quinapril's safety and efficacy, with ongoing post-marketing surveillance supporting its continued clinical use. There are no notable recent regulatory hurdles impacting quinapril's market trajectory.

Competitive Dynamics

The competitive landscape is dominated by generics, with a handful of pharmaceutical companies manufacturing quinapril globally. Major players include Teva Pharmaceutical Industries, Mylan, and Nichi-Iko Pharmaceutical, among others. The commoditized nature of generics exerts downward pressure on unit prices, limiting revenue growth per dose but maintaining steady sales volume.

Biotech and pharmaceutical companies are exploring fixed-dose combinations (FDCs) involving quinapril and other antihypertensives to differentiate offerings and extend product life cycles, usually through new patent filings or exclusivity periods [3].

Emerging Clinical and Market Trends

1. Formulation Innovations: Extended-release formulations and combination drugs enhance patient compliance, positioning quinapril as part of more sophisticated therapeutic regimens.

2. Shift Toward Personalized Medicine: Pharmacogenomics may influence quinapril prescribing, optimizing efficacy and tolerability across diverse populations.

3. Increasing Global Access: Expanding healthcare infrastructure in emerging markets (e.g., Asia-Pacific, Latin America) fosters increased demand, although pricing pressures and healthcare policies vary significantly.

4. Competition from Novel Agents: Angiotensin receptor blockers (ARBs) and direct renin inhibitors compete with quinapril by offering alternative therapeutic profiles, impacting its market share especially in regions where these are preferred due to side effect profiles.

Financial Trajectory and Revenue Outlook

The financial prospects for quinapril hinge heavily on generic sales volume and pricing strategies. With patent expiry over a decade ago, revenue historically declined for branded formulations but stabilized through:

• Market Penetration in Emerging Economies: Increased access and healthcare reforms have contributed to unimpaired sales volumes in these regions.
• Strategic Alliances and Licensing: Brand owners partnering with generic manufacturers to expand reach and ensure revenue streams.
• Differentiated Formulations: Development of combination or extended-release formulations supports premium pricing where patents or exclusivities are available.

Estimated global sales of quinapril are projected to hover around USD 200 million in 2023, with forecasts indicating modest CAGR of approximately 2-3% over the next five years, primarily driven by incremental demand in emerging markets [4].

Impact of Healthcare Policies and Guidelines

Guidelines favoring ACE inhibitors for certain patient populations promote consistent prescribing patterns. The declining trend in ACE inhibitor use in favor of ARBs in some markets—considered due to tolerability, especially regarding cough—may marginally suppress overall quinapril revenues. However, cost-effectiveness of generics sustains its market presence.

Potential Future Developments

• Patent Playouts: Any new patent filings, such as for novel formulations or delivery systems, could temporarily boost revenues.
• Regulatory Incentives: Orphan drug designations or broader indications may create new market opportunities.
• Digital Health Integration: Remote monitoring and adherence programs could enhance prescribing volumes and patient compliance.

Key Challenges and Risks

• Generic Price Erosion: Continued competition and price competition diminish profit margins.
• Market Saturation: Mature markets like North America and Europe exhibit limited growth potential.
• Competitive Substitutes: The rise of ARBs and newer agents could further erode quinapril's market share.
• Regulatory Changes: Stringent regulations and evolving healthcare policies might impact manufacturing or marketing strategies.

---

Key Takeaways

• The quinapril hydrochloride market is mature with significant generic penetration, constraining revenue growth but ensuring steady sales volumes.
• Emerging markets and formulation innovations offer avenues for growth despite intense price competition.
• Strategic development of combination therapies and new formulations could extend quinapril’s commercial viability.
• Market dynamics are increasingly shaped by competition from ARBs and other antihypertensive classes, influencing prescribing trends.
• The financial trajectory is modest, with projected CAGR of 2-3% over the next five years, primarily driven by global access expansion and formulation differentiation.

---

FAQs

1. How has patent expiry impacted quinapril's market revenue?
Patent expiry around 2004-2005 led to a surge in generic manufacturing, drastically reducing brand-name prices and profit margins but stabilizing overall sales volume. Current revenues primarily derive from generic sales with minimal brand influence.

2. What are the primary competitors to quinapril in the antihypertensive market?
ARBs like losartan, valsartan, and telmisartan are the main competitors, often favored for better tolerability. Other ACE inhibitors such as enalapril and ramipril also compete within the same therapeutic class.

3. Are there emerging formulations that could revive quinapril's market?
Yes, extended-release formulations and fixed-dose combinations (FDCs) incorporating quinapril may enhance patient compliance and enable premium pricing, potentially revitalizing market prospects.

4. What role do healthcare policies in emerging markets play in quinapril’s growth?
Policies promoting access to affordable antihypertensive medications foster increased demand for generic quinapril, supporting growth in these regions despite pricing pressures.

5. What strategic actions can manufacturers take to optimize quinapril revenue?
Investing in innovative formulations, expanding into new markets, forming strategic alliances, and developing combination therapies are key strategies to extend product lifecycle and profitability.

---

References

[1] Grand View Research, "ACE Inhibitors Market Size, Share & Trends Analysis," 2022.

[2] U.S. Food and Drug Administration, "Drug Approvals and Patents," 2023.

[3] MarketWatch, "Pharmaceutical Industry Trends and Opportunities," 2022.

[4] EvaluatePharma, "Global Cardiovascular Drugs Overview," 2023.